Transcriptomic effects of adenosine 2A receptor deletion in healthy and endotoxemic murine myocardium

Abstract

Influences of adenosine 2A receptor (A_2AR) activity on the cardiac transcriptome and genesis of endotoxemic myocarditis are unclear. We applied transcriptomic profiling (39 K Affymetrix arrays) to identify A_2AR-sensitive molecules, revealed by receptor knockout (KO), in healthy and endotoxemic hearts. Baseline cardiac function was unaltered and only 37 A_2AR-sensitive genes modified by A_2AR KO (≥1.2-fold change, <5 % FDR); the five most induced are Mtr, Ppbp, Chac1, Ctsk and Cnpy2 and the five most repressed are Hp, Yipf4, Acta1, Cidec and Map3k2. Few canonical paths were impacted, with altered Gnb1, Prkar2b, Pde3b and Map3k2 (among others) implicating modified G protein/cAMP/PKA and cGMP/NOS signalling. Lipopolysaccharide (LPS; 20 mg/kg) challenge for 24 h modified >4100 transcripts in wild-type (WT) myocardium (≥1.5-fold change, FDR < 1 %); the most induced are Lcn2 (+590); Saa3 (+516); Serpina3n (+122); Cxcl9 (+101) and Cxcl1 (+89) and the most repressed are Car3 (−38); Adipoq (−17); Atgrl1/Aplnr (−14); H19 (−11) and Itga8 (−8). Canonical responses centred on inflammation, immunity, cell death and remodelling, with pronounced amplification of toll-like receptor (TLR) and underlying JAK-STAT, NFκB and MAPK pathways, and a ‘cardio-depressant’ profile encompassing suppressed ß-adrenergic, PKA and Ca²⁺ signalling, electromechanical and mitochondrial function (and major shifts in transcripts impacting function/injury including Lcn2, S100a8/S100a9, Icam1/Vcam and Nox2 induction, and Adipoq, Igf1 and Aplnr repression). Endotoxemic responses were selectively modified by A_2AR KO, supporting inflammatory suppression via A_2AR sensitive shifts in regulators of NFκB and JAK-STAT signalling (IκBζ, IκBα, STAT1, CDKN1a and RRAS2) without impacting the cardio-depressant gene profile. Data indicate A_2ARs exert minor effects in un-stressed myocardium and selectively suppress NFκB and JAK-STAT signalling and cardiac injury without influencing cardiac depression in endotoxemia.

Electronic supplementary material

The online version of this article (doi:10.1007/s11302-016-9536-1) contains supplementary material, which is available to authorized users.

Introduction

Uncontrolled inflammation with sepsis and the systemic inflammatory response syndrome induce multiple organ dysfunction, including cardiac abnormalities key to disease progression and mortality [1]. Unravelling the complex mechanisms governing myocardial injury [1, 2] is not only fundamentally important but also reveals targets for manipulating outcomes. In this regard, adenosine 2A receptors (A_2ARs) may fulfil a broadly suppressive role to limit inflammatory injury in multiple tissues [3–6] and enhance myocardial resistance to ischaemic/hypoxic insult, presenting a potentially useful therapeutic target [3, 7]. In heart, this G protein-coupled receptor (GPCR) influences coronary tone and angiogenesis, cardiac contractility, fibroblast growth and fibrosis and may mediate protection via ischaemic pre- and post-conditioning [8–10]. Inflammatory modulation contributes to this latter cardioprotection [9–11], together with the regulation of myocyte kinase signals to limit oxidative stress, mitochondrial dysfunction and cell death [12–14]. However, impacts of the A_2AR on integrated myocardial responses to uncontrolled inflammation, and the mechanisms underlying such effects, remain to be elucidated.

While adenosine analogues and A_2AR agonists can limit endotoxemic or septic injury in lung [15, 16], liver [17], brain [18] and heart [19–21], the roles of intrinsic A_2AR activity are less clear. Receptor deletion fails to modify inflammatory markers/injury in some studies [22], reportedly worsens endotoxemic injury in heart [23] and lung [15, 24] and improves survival in models of polymicrobial sepsis [25, 26]. These divergent outcomes may reflect different cell- and organ-specific effects of A_2ARs, for example promoting inflammasome formation and macrophage-dependent injury [27], impairing bacterial clearance [25], while activating cardiac survival signalling and suppressing inflammation [3, 7, 12–14]. Nonetheless, opposing effects of endogenous vs. exogenous (or amplified endogenous) adenosine are evident within cell types, for example inhibiting vs. promoting vascular myocyte NOS activation with inflammation [28]. The chronicity of receptor activation may also be critical to tissue-specific responses; while acute or transient increases in adenosine levels/receptor activity are generally beneficial (improving tissue perfusion, ischemic/hypoxic tolerance and reducing cytokines/inflammation), chronic elevations may be detrimental, exaggerating fibrotic processes via A_2BRs in lung [29] or A_2A and A_2BRs in liver [30, 31], for example. Whether acute vs. chronic A_2AR activity induces opposing myocardial outcomes is unknown, though prolonged A_2B agonism limits rather than promotes fibrosis in injured myocardium [32], as does prolonged A₁ agonism [33].

Additional to questions regarding protective vs. deleterious effects of the A_2AR, the evolution of myocardial inflammatory injury and ‘endotoxemic myocarditis’ itself is complex and incompletely defined [1, 2]. Effects in non-cardiac tissues involve TLR/CD14-dependent NFκB and MAPK signalling and interferon/cytokine engagement of the JAK-STAT path [34–36]. These mechanisms likely participate in heart, with evidence NFκB and IκB kinase promotes cardiac dysfunction in sepsis/endotoxemia [37, 38], while JAK-STAT signalling mediates dysfunction and cell death in myocardial ischemia [39, 40]. In vivo observations suggest marked expansion of this signalling in intact myocardium [41, 42], contrasting in vitro evidence that cardiomyocyte NFκB and IκB kinase signalling is only transiently LPS responsive [43]. Importantly, these paths are inhibited by A_2ARs in other cells, with exogenous agonism decreasing [44, 45] and A_2AR KO increasing NFκB activity [6]. Nonetheless, these paths can also promote myocardial stress-resistance and survival under conditions that include inflammatory cytokine challenge [46–48]. The molecular underpinnings of endotoxemic myocarditis in vivo warrant further investigation, as do the mechanisms countering this dysfunction (including A_2AR activity). We thus undertook broad-scale transcriptomic profiling of hearts from WT and A_2AR KO mice, at baseline and following endotoxin challenge: shifts in gene expression can shed light on both functions of the A_2AR, and pathogenesis and modulation of endotoxemic myocarditis. There are no prior analyses of transcriptome-wide effects of A_2AR activity in myocardium, and relatively few of the in situ cardiac response to endotoxemia or sepsis [41, 42, 49].

Materials and methods

Animals

All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the NIH (publication number 85-25, revised 1996). This project (and protocols for care of animals) was approved by the Animal Care and Use Committees of St. Jude Children’s Research Hospital and the University of Tennessee Health Sciences Center. The A_2AR KO mice and WT littermates were obtained from a sub-colony of the original lines generated and characterized by Ledent et al. [50]. Analysis of cardiac tissue confirms ablation of A_2AR transcript without compensatory shifts in other adenosine receptors (Fig. S1). Mice were bred and maintained on-site at St. Jude Children’s Research Hospital, with standard laboratory food and water available ad libitum. Animal genotype was confirmed by PCR analysis of tail snips. All animals were originated from the same breeding series and were matched for age and weight. Male and female mice were used with equal representation in each experimental group. Both A_2AR KO and WT littermate mice were randomly allocated to receive either an intraperitoneal injection of 20 mg/kg LPS isolated from E. coli (Sigma-Aldrich, St. Louis, MO) or an equal volume of sterile saline vehicle. Blood was sampled at 12 and 24 h of LPS challenge to assess shifts in blood cell counts and circulating cytokines/biomarkers, as detailed by us previously [23]. Mice were monitored for the development of symptoms of illness or distress (lethargy, piloerection, hunched posture and/or respiratory distress) during the initial 12 h post-injection and every 4 h thereafter; observation of any combination of symptoms prompted immediate euthanasia. All efforts were made to minimize animal suffering and distress. No analgesic or anaesthetic was administered other than for euthanasia immediately on evidence of illness/distress.

We initially tested responses to 24 h LPS challenge in both young (14 week) and old (46–52 weeks) WT and A_2AR KO mice. However, absent overt symptoms of illness/distress, there was nonetheless significant mortality in aged LPS-treated mice, as detailed in the “Results” section and in Supplementary material. Cause of death in older animals was not determined. As a result of mortality, detailed molecular interrogation of cardiac gene expression (n = 6–8 per group), together with analyses of cardiac function in isolated hearts (n = 8–9 per group) and haematological/biomarker assessment (n = 6–9 per group) is necessarily constrained to the young group of mice.

Langendorff perfusion and tissue sampling

After 24 h of LPS challenge, mice were anaesthetised with sodium pentobarbital (50 mg/kg intraperitoneally), a thoracotomy performed and hearts excised into ice-cold Krebs-Henseleit solution for Langendorff perfusion, as detailed previously [23], or sampling of ventricular tissue for RNA preparation. Briefly, for perfusions, the aorta was immediately cannulated and hearts perfused at 80 mmHg with modified Krebs-Henseleit solution containing (in mM): NaCl, 120; NaHCO3, 25; KCl, 4.7; CaCl2, 2.5; MgCl2, 1.2; KH2PO4, 1.2; D-glucose, 15 and EDTA, 0.5. Perfusion fluid was maintained at 37 °C and bubbled with a mix of 95 % O2/5 % CO2 at 37 °C to provide a pH of 7.4. Ventricular function was monitored via a fluid-filled plastic film balloon in the left ventricle, connected to a P23 XL pressure transducer (Viggo-Spectramed, Oxnard, CA, USA). Coronary flow was monitored via a flow-probe in the aortic perfusion line, connected to a T206 flowmeter (Transonic Systems Inc., Ithaca, NY, USA). Functional data were recorded at 1 KHz on MacLab data acquisition system (ADInstruments, Castle Hill, Australia). Statistical comparisons of cardiovascular (Table 1) and blood parameters (Figs. 1 and 2) between groups were made via analysis of variance (ANOVA), with a Newman-Keuls post hoc test for specific comparisons. A P < 0.05 was considered indicative of significance in all tests.

Table 1.

Ex vivo cardiovascular function in perfused for hearts from WT and A_2AR KO mice

Functional parameter	WT (n = 8)	A2AR KO (n = 8)	WT + LPS (n = 9)	A2AR KO + LPS(n = 9)
Coronary flow (ml/min/g)	16.7 ± 0.7	15.6 ± 1.2	16.9 ± 1.7	15.9 ± 0.6
Heart rate (beats/min)	341 ± 7	341 ± 7	352 ± 9	353 ± 9
Systolic pressure (mmHg)	113 ± 6	118 ± 5	80 ± 7*	86 ± 3*
+dP/dt (mmHg/s)	6039 ± 247	6039 ± 163	4310 ± 422*	4489 ± 220*
−dP/dt (mmHg/s)	−3664 ± 129	−3718 ± 132	2666 ± 197*	−2846 ± 105*
Coronary ‘Supply:Demand’ (ml/min/g/mmHg)	0.15 ± 0.01	0.13 ± 0.02	0.21 ± 0.02*	0.18 ± 0.02*

All data are means ± S.E.M. Functional parameters were measured after 30 min of normothermic aerobic perfusion. Intrinsic heart rate is recorded immediately prior to pacing. *P < 0.05 vs. corresponding values in Vehicle-treated hearts. Coronary ‘Supply:Demand’ was calculated as the ratio of coronary flow rate (O₂ supply) relative to ventricular systolic pressure (reflecting myocardial O₂ demand). dP/dt, first derivative of pressure over time. *P < 0.05 vs. untreated. A_2AR KO did not independently modify functional parameters

Fig. 1.

Effects of A_2AR KO and LPS (24 h) on markers of cardiac damage (TnI) and systemic inflammation (CRP) and the acute phase response (haptoglobin). Data represent means ± S.E.M. *P < 0.05 vs. vehicle; †P < 0.05 vs. wild-type

Fig. 2.

Effects of A_2AR KO and LPS (24 h) on haematological parameters and cytokines. Data represent means ± S.E.M. *P < 0.05 vs. vehicle; †P < 0.05 vs. wild-type

RNA preparation and microarray hybridisation

Ventricular tissue was isolated, frozen in liquid N₂ and stored at −80 °C until analysis. Tissue was subsequently homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA) and total RNA isolated according to manufacturer’s protocol. The RNA was further treated with 50 U of DNase I (Promega, Madison, WI) for 15 min at 37 °C and purified on RNeasy spin columns (Qiagen, Hilden, Germany). Total RNA yield and integrity were determined spectrophotometrically and via capillary electrophoresis on a 2100 BioAnalyzer (Agilent, Palo Alto, CA), respectively.

Microarray experiments were performed at the St. Jude Hartwell Center Core Facility according to manufacturers’ protocols. Briefly, first- and second-strand complementary DNA (cDNA) synthesis reactions were performed using the SuperScript Choice System (Invitrogen, Carlsbad, CA) followed by in vitro transcription using biotin-labelled dNTPs (ENZO Diagnostics, Farmingdale, NY). Complementary RNA (cRNA) samples were fragmented and individually hybridized to GeneChip® Mouse Genome 430 2.0 microarrays (Affymetrix, Santa Clara, CA). Each microarray quantified expression of over 39,000 transcripts, including full-length mRNA sequences and expressed sequence tags (ESTs). Following hybridization, microarrays were washed and stained with streptavidin–phycoerythrin (Molecular Probes, Eugene, OR) before scanning. Image files were converted into probe-set data (*.CEL files) via Affymetrix MAS 5.0 software. Experimental data are accessible through GEO Series accession number GSE44363 at http://www.ncbi.nlm.nih.gov/geo.

Microarray data and statistical analyses

Raw expression data were background corrected, normalized and log₂ transformed using the Robust Multichip Average (RMA) method in BioConductor/R [51]. Data were filtered to include only transcripts detected on ≥3 arrays, with 25,646 transcripts passing this quality criterion (i.e. consistently detected in cardiac tissue). Log₂ ratio values were generated by subtracting median expression values for WT vehicle-treated animals from each sample per probe before importing into TIGR MeV 4.0 software for statistical analysis [52]. The Significant Analysis of Microarrays (SAM) algorithm was used to correct for multiple comparisons and non-parametrically select differentially expressed genes using a median false discovery rate (FDR) ≤1.0 % [53]. In addition, a two-factor analysis of variance (ANOVA) was performed. To generate a data sets similar in size and false-positive rates, a P value <0.005 was employed. The lists of differentially expressed genes generated via SAM or ANOVA were then compared to identify 8110 shared transcripts for further investigation and validation (Fig. S2). This output was subjected to appropriate pair-wise SAM comparisons, incorporating a 1.5-fold change cut-off [54]. Significant transcripts were annotated using Ingenuity Pathway Analysis (IPA) (v8.7; Ingenuity® Systems, Redwood City, CA, USA), providing insight into biological/molecular themes over-represented in response to A_2AR deletion and/or LPS. In brief, for each pathway/process, the fraction of differentially expressed genes was compared with the fraction of total genes in that path (shown in tables as the ‘Ratio’, useful for determining which pathways/processes overlap the most with altered genes in specific datasets). The probability of involvement of the respective number of modified transcripts in a path/process is expressed as a P value or range (values <0.05 considered significant).

Validation of expression changes and Adora expression via RT-qPCR

Two-step RT-qPCR, utilizing SYBR Green I, was employed to confirm differential gene expression for 11 transcripts (primer details provided in Table S1), as previously described [54]. Six additional genes (Actb, Gapdh, Hprt1, Pgk1, Ppia and Ubc) were assessed using GeNorm to determine utility as reference genes [55]. Following GeNorm assessment, Actb was found to be most stable (M = 0.03) and served as the endogenous reference control for all messenger RNAs (mRNAs) assessed via RT-qPCR. Briefly, 1 μg total RNA was used to synthesize cDNA using the Superscript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions. RT-qPCR was performed in a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Final reaction volumes (10 μL) included 5 μL iQ SYBR-Green Supermix (Bio-Rad, Hercules, CA), 100 nM of each primer and 4 μL of a 1:20 dilution of cDNA. Optimal qPCR cycling conditions entailed an initial denaturation at 95 °C for 3 min followed by 40 cycles of 95 °C for 15 s/62 °C for 60 s. After the final PCR cycle, reactions underwent melt curve analysis to detect non-specific amplicons. All reactions were performed in triplicate, with each plate containing an equal number of samples from each group, a calibrator control derived from a pool of all cDNA samples and a no-template control. PCR amplification efficiencies (90–110 %) for each primer pair were calculated using a 5-log serial dilution of calibrator sample. PCR data were analysed using CFX Manager v1.6 (Bio-Rad, Hercules, CA). Baseline subtractions and threshold settings above background were applied to all data. The calibrator sample was used to normalize inter-assay variations, with the threshold coefficient of variance for intra- and inter-assay replicates <1 % and <5 %, respectively. Normalized expression (ΔΔC_q) was calculated, with mRNAs normalized to Actb levels and the calibrator control then log₂-transformed.

Results

Impact of A_2AAR deletion on cardiovascular function and inflammatory markers

Deletion of the A_2AR was confirmed in cardiac tissue, with no compensatory changes in transcription of the other three sub-types (Fig. S1). Receptor deletion did not modify cardiac or coronary function in healthy or endotoxemic hearts (Table 1). Cardiovascular, blood cell and cytokine responses to LPS in WT and A_2AR KO mice have been reported by us previously [23]. Similar outcomes were apparent here for markers of inflammation and injury (Fig. 1), haematological parameters and cytokines (Fig. 2) and cardiac function (Table 1). Data confirm significant inflammatory activation, cellular injury and cardiac dysfunction with LPS, with A_2AR deletion amplifying changes in IL-5 and markers of cardiac injury (TnI) and systemic inflammatory stress (haptoglobin, CRP), without altering myocardial dysfunction or circulating levels of IL-4, IL-10, IFNγ or TNFα.

Impact of A_2AAR deletion on survival

Interestingly, we acquire preliminary evidence LPS-dependent mortality is age- and sex-dependent and selectively exaggerated by A_2AR KO in older males (Fig. S3). Initially, testing responses to LPS challenge in young (14 week) and middle-aged (46–52 week) mice—since age may exaggerate impacts of endotoxemia [56]—we recorded 20 % mortality in older WT mice with A_2AR KO specifically reducing survival to <20 % in older males (Fig. S3). No mortality was recorded in young mice challenged with LPS (or any vehicle-treated groups). There is thus a trend to greater mortality with age, with a major survival effect of A_2AR activity in older males. While molecular interrogations here are thus limited to young mice (in which LPS was non-lethal), it is possible A_2AR activity may be increasingly crucial to survival in older, stress-intolerant males (whereas younger animals and females may possess intrinsically greater resistance to injury/death [57]). This is discussed further in the online Supplementary material.

Cardiac transcriptomic response to A_2AR KO

Few transcriptional differences were detected between WT and A_2AR KO hearts, with the amplitude of changes modest (up to threefold). Employing an initial 1.5-fold cut-off and 1 % FDR identified only 13 genes (Table 2). To enhance the power of subsequent pathway analysis, these criteria were relaxed to 1.2-fold and 5 %, encompassing 37 altered transcripts (Table 2). There was a little impact of A_2AR deletion on inflammatory mediators, with modest induction of a CXC chemokine (Ppbp, +2.1), a regulator of cell migration/adhesion and cytokinesis (Iqgap1, +1.6) and a hemopoietic cytokine (Tslp, +1.6), together with repression of Hp (−2.7) and an Ig adhesion molecule regulating T-lymphocyte development (Mpzl2, −1.7) (Table 2).

Table 2.

Genes modified by A_2AR KO in healthy myocardium

Gene	Gene name	Affymetrix ID	Fold-Change	%FDR
UpRegulated
Mtr	5-methyltetrahydrofolate-homocysteine methyltransferase	1439811_at	2.83	0.00
Ppbp	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)	1418480_at	2.08	3.93
Chac1	ChaC, cation transport regulator homologue 1 (E. coli)	1451382_at	1.85	0.00
Ctsk	cathepsin K	1450652_at	1.84	0.00
Cnpy2	canopy 2 homologue (zebrafish)	1416507_at	1.67	0.00
Iqgap1	IQ motif containing GTPase activating protein 1	1445724_at	1.64	3.85
Tslp	thymic stromal lymphopoietin	1450004_at	1.63	3.93
Nav3	neuron navigator 3	1456144_at	1.61	0.00
Cux2	cut-like homeobox 2	1447500_at	1.60	0.00
Slc38a1	solute carrier family 38, member 1	1454764_s_at	1.47	0.00
Nsmce1	non-SMC element 1 homologue (S. cerevisiae)	1436121_a_at	1.42	0.00
Gk5	glycerol kinase 5 (putative)	1436210_at	1.38	3.93
Rpl22	ribosomal protein L22	1448398_s_at	1.37	0.00
C11orf75	chromosome 11 open reading frame 75	1419403_at	1.37	0.00
Slco5a1	solute carrier organic anion transporter family, member 5 A1	1440874_at	1.31	4.21
Nfatc2	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2	1426032_at	1.28	4.70
Downregulated
Dgat1	diacylglycerol O-acyltransferase homologue 1 (mouse)	1418295_s_at	−1.24	2.39
Ticam1	toll-like receptor adaptor molecule 1	1454676_s_at	−1.24	3.05
Mrap	melanocortin 2 receptor accessory protein	1451371_at	−1.31	3.05
Ppa1	pyrophosphatase (inorganic) 1	1416939_at	−1.32	4.31
Ell2	elongation factor, RNA polymerase II, 2	1450744_at	−1.33	2.53
Fmod	fibromodulin	1456084_x_at	−1.47	4.31
Ptger3	prostaglandin E receptor 3 (subtype EP3)	1450344_a_at	−1.49	2.68
Pkdcc	protein kinase domain containing, cytoplasmic homologue (mouse)	1454838_s_at	−1.50	4.61
Ank3	ankyrin 3, node of Ranvier (ankyrin G)	1457288_at	−1.58	3.05
Sacs	spastic ataxia of Charlevoix-Saguenay (sacsin)	1434958_at	−1.61	2.39
Pon1	paraoxonase 1	1418190_at	−1.68	0.00
Gnb1	guanine nucleotide binding protein (G protein), beta polypeptide 1	1425908_at	−1.72	4.54
Mpzl2	myelin protein zero-like 2	1416236_a_at	−1.74	0.00
Pde3b	phosphodiesterase 3B, cGMP-inhibited	1433694_at	−1.74	0.00
Prkar2b	protein kinase, cAMP-dependent, regulatory, type II, beta	1438664_at	−1.78	3.05
Slc16a9	solute carrier family 16, member 9 (monocarboxylic acid transporter 9)	1429726_at	−1.84	0.00
Map3k2	mitogen-activated protein kinase kinase kinase 2 (MEKK2)	1438719_at	−2.01	0.00
Cidec	cell death-inducing DFFA-like effector c	1452260_at	−2.08	0.00
Acta1	actin, alpha 1, skeletal muscle	1427735_a_at	−2.14	2.68
Yipf4	Yip1 domain family, member 4	1426417_at	−2.51	4.54
Hp	haptoglobin	1448881_at	−2.70	0.00

Data shown for transcripts for which myocardial expression levels were modified by A_2AR KO by a factor of ≥1.2-fold (FDR <5 %)

Analysis via the IPA suite identified 112 canonical pathways sensitive to A_2AR activity in healthy hearts (Table S2), the most highly modified shown in Table 3. The top five included relaxin signalling, cardiac β-adrenergic signalling, cellular effects of sildenafil, PKA signalling and photo-transduction. The influence of A_2AR KO on these and other paths can be attributed to repression of Prkar2b (−1.8), Gnb1 (−1.7) and Pde3b (−1.7), collectively impacting G protein-coupled cAMP/PKA dependent signalling (encompassing relaxin, α- and β-adrenergic, NO, Ca²⁺ and hypertrophic signalling). Additionally, Map3k2 (−2) and Nfat2c (+1.3) span many paths modified by A_2AR KO. Modulation of these five transcripts contributes to 48 of the top 50 A_2AR-sensitive canonical pathways. Overall, A_2AR deletion exerts an inhibitory effect on G protein-coupled, cAMP/PKA, and MEKK2 signalling downstream of this and other GPCRs.

Table 3.

Top 20 canonical pathways modified by A_2AAR KO in healthy myocardium

Canonical pathways	P value	Ratio	Genes
Relaxin signalling	3.55E-03	1.99E-02	Gnb1, Prkar2b, Pde3b
Cardiac β-adrenergic signalling	3.55E-03	2.11E-02	Gnb1, Prkar2b, Pde3b
Cellular effects of sildenafil (Viagra)	3.98E-03	1.99E-02	Acta1, Prkar2b, Pde3b
Protein Kinase A signalling	6.03E-03	1.26E-02	Gnb1, Prkar2b, Pde3b, Nfatc2
Phototransduction pathway	6.03E-03	3.08E-02	Gnb1, Prkar2b
Germ cell-sertoli cell junction signalling	6.31E-03	1.88E-02	Iqgap1, Acta1, Map3k2
Calcium signalling	8.71E-03	1.47E-02	Prkar2b, Nfatc2, Acta1
Glutamate receptor signalling	9.55E-03	2.86E-02	Gnb1, Slc38a1
Caveolar-mediated endocytosis signalling	1.41E-02	2.35E-02	Acta1, Map3K2
Nitric oxide signalling in the cardiovascular system	1.48E-02	2.02E-02	Prkar2b, Pde3b
Leptin signalling in obesity	1.55E-02	2.38E-02	Prkar2b, Pde3b
Cardiac hypertrophy signalling	1.78E-02	1.22E-02	Gnb1, Prkar2b, Map3k2
TR/RXR Activation	2.09E-02	2.02E-02	Hp, Pde3b
SAPK/JNK signalling	2.14E-02	1.98E-02	Gnb1, Map3k2
Colorectal cancer metastasis signalling	2.14E-02	1.17E-02	Gnb1, Prkar2b, Ptger3
α-Adrenergic signalling	2.19E-02	1.89E-02	Gnb1, Prkar2b
RANK signalling in osteoclasts	2.19E-02	2.04E-02	Nfatc2, Map3K2
G Beta Gamma signalling	2.24E-02	1.68E-02	Gnb1, Prkar2b
IL-1 signalling	2.29E-02	1.89E-02	Gnb1, Prkar2b
fMLP signalling in neutrophils	2.95E-02	1.57E-02	Gnb1, Nfatc2

Canonical signalling paths modified by A_2AR KO are shown, ranked according to P values determined by a Fisher’s Exact Test. Also shown is a ratio value reflecting the number of molecules in a given path that meet cut-off criteria for differential expression, divided by the total number of molecules in the pathway

Multiple biological functions appear sensitive to A_2AR KO (see Table S3), the most significant (Table 4) revolving around cellular development, growth, movement and death, together with humoral immunity and haematological development and intercellular signalling. Toxicological functions included high representation of liver processes (fibrosis, damage, steatosis, hepatitis and inflammation) together with six cardiac functions (Table 4). The latter included cardiac arteriopathy (Ank3, Pon1, Cux2, Gk5, Pde3b, Dgat1 and Nsmce1), infarction (Pon1 and Acta1) and transcripts involved in failure and hypertrophy (Pde3b and Nfat2c).

Table 4.

Top 20 biological and toxicological functions modified by A_2AAR KO in healthy myocardium

Biological pathway	P values	Genes
Cellular development	7.34E-04–4.5E-02	Mrap, Ctsk, Sacs, Prkar2b, Ptger3, Nfatc2, Tslp, Map3k2
Cellular growth and proliferation	7.34E-04–4.01E-02	Mrap, Ppbp, Nfatc2, Tslp
Haematological system development and function	7.34E-04–4.5E-02	Hp, Ptger3, Ticam1, Ppbp, Nfatc2, Tslp, Map3k2
Humoral immune response	7.34E-04–4.5E-02	Nfatc2, Fmod, Tslp
Cell-to-cell signalling and interaction	1.53E-03–4.74E-02	Ank3, Ptger3, Ticam1, Ppbp, Nfatc2, Iqgap1, Tslp, Map3k2
Amino acid metabolism	2.55E-03–5.09E-03	Slc38a1
Carbohydrate metabolism	2.55E-03–4.72E-02	Gnb1, Pon1, Ppbp, Ppa1
Cell death	2.55E-03–4.5E-02	Ppbp, Nfatc2, Tslp, Map3k2
Cell morphology	2.55E-03–3.68E-02	Ank3, Ptger3, Nfatc2, Cnpy2, Iqgap1, Tslp
Cellular assembly and organization	2.55E-03–4.01E-02	Ank3, Ctsk, Nfatc2, Fmod, Cnpy2, Iqgap1, Acta1
Cellular compromise	2.55E-03–4.01E-02	Ank3, Hp, Ctsk, Ptger3, Ppbp
Cellular function and maintenance	2.55E-03–1.52E-02	Hp, Ppbp, Nfatc2, Tslp, Map3k2
Cellular movement	2.55E-03–4.58E-02	Gnb1, Ctsk, Hp, Ticam1, Ppbp, Nfatc2, Iqgap1, Tslp
Connective tissue development and function	2.55E-03–3.02E-02	Ctsk, Rpl22, Ptger3, Pde3b, Ppbp, Cidec, Nfatc2
Connective tissue disorders	2.55E-03–5.09E-03	Nfatc2
Developmental disorder	2.55E-03–2.55E-03	Ctsk
Genetic disorder	2.55E-03–4.01E-02	Ank3, Ctsk, Ptger3, Cidec, Iqgap1, Tslp, Mrap, Gnb1, Pon1, Hp, Prkar2b, Pde3b, Nfatc2, Dgat1, Acta1
Hair and skin development and function	2.55E-03–5.09E-03	Ptger3, Dgat1
Immune cell trafficking	2.55E-03–3.51E-02	Hp, Ticam1, Ppbp, Nfatc2, Tslp
Inflammatory response	2.55E-03–4.67E-02	Hp, Ptger3, Ticam1, Ppbp, Nfatc2, Fmod, Tslp
Molecular toxicological function	P values	Genes
Liver fibrosis	3.01E-03	Hp, Tslp
Liver damage	1.43E-02	Ticam1, Tslp
Liver steatosis	2.45E-02	Pde3b
Cardiac arteriopathy	3.41E-02	Ank3, Cux2, Dgat1, Gk5, Nsmce1, Pde3b, Pon1
Cardiac infarction	3.76E-02	Acta1, Pon1
Liver hepatitis	4.41E-02	Pde3b
Hepatocellular carcinoma	4.43E-02	Hp, Iqgap1
Liver steatohepatitis	5.67E-02	Pde3b
Renal proliferation	7.90E-02	Tslp
Liver inflammation	9.36E-02	Hp
Pulmonary hypertension	1.08E-01	Ptger3
Nephrosis	1.10E-01	Pde3b
Cardiac congestive cardiac failure	1.63E-01	Pde3b
Heart failure	1.63E-01	Pde3b
Renal nephritis	2.50E-01	Pde3b

Enriched biological/toxicological functions of A_2AR KO sensitive transcripts are listed according to P values or ranges determined by a Fisher’s Exact Test

Cardiac transcriptomic response to LPS

Analysis via the SAM algorithm (1.5-fold threshold, 1 % FDR) identified 4146 transcripts modified after 24 h of LPS challenge (see Table S4 for full details). Figure 3 presents the 25 most induced and repressed transcripts, with responses in A_2AR KO hearts shown for comparison. Many of the most highly modified are predictably involved in inflammation/innate immunity, together with tissue development/remodelling. The most LPS-responsive cytokines/chemokines are shown in Fig. 4, with responses in KO hearts highlighted.

Fig. 3.

The 25 most induced and 25 most repressed transcripts in hearts from young (2–3 month) mice challenged with LPS for 24 h. Mice were injected with 20 mg/kg LPS or saline vehicle and left ventricular tissue isolated for analysis 24 h later. Data from both wild-type and A_2AR KO hearts are shown for comparison (n = 6–8/group). Data are means ± S.E.M

Fig. 4.

Effects of A_2AR KO on the most LPS-responsive cytokines in wild-type hearts. Mice were injected with 20 mg/kg LPS or saline vehicle, and left ventricular tissue isolated for analysis 24 h later. Data from both wild-type and A_2AR KO hearts are shown for comparison (n = 6–8/group). Data are means ± S.E.M

Functional classifications, using a twofold threshold to narrow the focus to the most highly modified paths, identify 236 canonical pathways (Table S5 ), with the most significantly modified presented in Table 5. Data confirm a profound inflammatory and immune response, with marked upregulation of TLR/MyD88 and interferon signalling (Fig. 5), the acute phase response (Fig. S4), IRF activation (Fig. S5) and PRR- and RIG-1-like signalling (Figs. S6 and S7). These changes primarily reflect shifts in underpinning NFκB, JAK-STAT, MAPK and PI3K/Akt signalling (Figs. S8–S12). Additionally, LPS upregulated cell death signalling (Figs. S13 and S14) and modified paths involved in cellular differentiation, movement, growth and remodelling (e.g. Figs. S15 and S17). The top LPS-sensitive biological functions are summarized in Table S6, with biologic and cardiovascular toxicological responses fully detailed in Table S7 and S8 in the Supplementary material.

Table 5.

Top 20 canonical pathways modified by LPS (≥2-fold change, <1 % FDR) in WT hearts

Canonical pathways	P value	Ratio	Genes
Acute phase response signalling	9.12E-09	2.02E-01	Socs3, Rac2, Hamp, Serping1, Nfkbie, Socs2, Cp, Saa2, Serpina3, Jak2, Il6, Rbp1, Nr3C1, C1r, Hmox1, Shc1, Nfkbia, Cfb, Lbp, Serpine1, Nfkbib, Saa1, C3, Tnfrsf1a, Myd88, C1s, Rac1, Serpinf1, Cebpb, Stat3, Nfkb2, Hp, Rras2, Il1Rn, C4a, C2
Interferon signalling	1.82E-08	4.33E-01	Ifit3, Oas1, Ptpn2, Mx1, Ifi35, Irf9, Psmb8, Jak2, Tap1, Irf1, Ifitm1, Stat2, Stat1
Activation of IRF by cytosolic pattern recognition receptors	1.38E-07	2.33E-01	Dhx58, Nfkbie, Zbp1, Irf9, Tbk1, Il6, Nfkb2, Adar, Isg15, Ifih1, Irf7, Nfkbia, Ddx58, Stat2, Nfkbib, Stat1, Ifit2
Hepatic fibrosis/hepatic stellate cell activation	7.94E-07	2.01E-01	Icam1, Lepr, Myh7b (Includes Eg:668,940), Myh11, Ccl5, Il6, Fas, Pgf, Vegfa, Il1r2, Cxcl3, Igf1, Cyp2e1, Timp1, Lbp, Stat1, Timp2, Egfr, Il4r, Vcam1, Tnfrsf1a, Vegfc, Igfbp5, Nfkb2, Myl7, Csf1, Cd14
Dendritic cell maturation	9.12E-07	1.51E-01	B2m, Rac2, Icam1, Lepr, Nfkbie, Pik3r5, Cd83, Il6, Jak2, Fcgr2b, Fcgr1a, Nfkbia, Hla-b, Tlr3, Stat1, Nfkbib, Fcgr3a, Hla-c, Myd88, Tnfrsf1a, Relb, Rac1, Nfkb2, Tlr2, Il1rn, Fcer1g, Stat2, Irf8
Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis	2.57E-06	1.34E-01	Socs3, Rac2, Icam1, Mmp3, Nfkbie, Pik3r5, Jak2, Ccl5, Il6, Il17ra, Fcgr1a, Pgf, Myc, C1r, Il1r2, Vegfa, Nfkbia, Traf3Ip2, Wif1, Cfb, Plcb1, Tlr3, Nfkbib, Prkd1, Fcgr3a, Calm1, Adamts4, Sele, Vcam1, Myd88, Tnfrsf1a, C1s, Daam1, Rac1, Vegfc, Stat3, Cebpb, Irak3, Tlr2, Hp, Rras2, Il1Rn, Csf1, Cxcl12, Cebpd, Sost, Wnt5a, Irak2
Retinoic acid mediated apoptosis signalling	5.37E-06	1.94E-01	Parp10, Art1, Tnfsf10, Parp3, Parp12, Parp9, Tiparp, Irf1, Parp4, Bid, Parp11, Cflar, Parp14
Antigen presentation pathway	6.61E-06	2.56E-01	B2m, Psmb9, Hla-e, Hla-b, Psmb8, Hla-g, Tap1, Tap2, Tapbp, Hla-c
Role of pattern recognition receptors in recognition of bacteria and viruses	8.32E-06	2.12E-01	Ptx3, Oas1, C3, Oas2, Myd88, Pik3R5, Il6, Nfkb2, Ccl5, Tlr2, Ifih1, Clec7a, Irf7, Syk, Ddx58, Eif2ak2, Tlr3
Death receptor signalling	1.29E-05	2.34E-01	Hspb3, Tnfrsf1a, Nfkbie, Tnfsf10, Tbk1, Nfkb2, Fas, Daxx, Nfkbia, Bid, Cflar, Nfkbib, Birc3, Birc2, Hspb1
IL-10 signalling	3.24E-05	2.14E-01	Ccr1, Socs3, Il4r, Nfkbie, Il6, Stat3, Nfkb2, Fcgr2b, Il1r2, Hmox1, Nfkbia, Il1rn, Cd14, Lbp, Nfkbib
Role of RIG1-like receptors in antiviral innate immunity	6.61E-05	1.96E-01	Dhx58, Ifih1, Irf7, Nfkbia, Nfkbie, Ddx58, Tbk1, Nfkb2, Nfkbib, Trim25
IL-6 signalling	1.00E-04	1.94E-01	Hspb3, Tnfrsf1a, Nfkbie, Il6, Nfkb2, Stat3, Cebpb, Jak2, Il1r2, Shc1, Nfkbia, Rras2, Il1rn, Cd14, Lbp, Nfkbib, Tnfaip6, Hspb1
IL-8 signalling	1.02E-04	1.45E-01	Rac2, Icam1, Cxcl1, Pik3r5, Pgf, Eif4ebp1, Vegfa, Hmox1, Gng11, Gna13, Nfkbib, Prkd1, Egfr, Vcam1, Rhoc, Rac1, Vegfc, Irak3, Cstb, Myl7, Myl9 (Includes Eg:98,932), Bcl2l1, Itgb2, Rras2, Ccnd2, Itgam, Irak2
Bladder cancer signalling	1.26E-04	1.89E-01	Fgf16, Mmp3, Fgf9, Mmp14, Mmp15, Vegfc, Pgf, Myc, Vegfa, Rras2, Mmp8, Fgf12, Cdkn1a, Chd1 (Includes Eg:1105), Rps6Ka5, Fgf7, Egfr
Pathogenesis of multiple sclerosis	1.45E-04	5.56E-01	Cxcl10, Ccr1, Cxcl9, Ccl5, Cxcl11
Role of PKR in interferon induction and antiviral response	1.58E-04	2.39E-01	Nfkbia, Tnfrsf1a, Nfkbie, Bid, Nfkb2, Eif2ak2, Tlr3, Stat1, Nfkbib, Fcgr1a, Irf1
JAK/Stat signalling	2.00E-04	2.19E-01	Rac2, Socs3, Pias2, Socs2, Rac1, Pik3r5, Stat3, Jak2, Shc1, Rras2, Cdkn1a, Cish, Stat2, Stat1
Complement system	2.09E-04	2.5E-01	C1R, Cfd, Serping1, C3, C1S, Cfb, C4a, Masp1, C2
Glucocorticoid receptor signalling	2.14E-04	1.25E-01	Rac2, Icam1, Nfkbie, Pik3R5, Pbx1, Ccl5, Jak2, Il6, Fcgr1a, Nr3c1, Il1R2, Shc1, Cxcl3, Hspa4, Nfkbia, Ar, Ccl13, Cdkn1c, Serpine1, Stat1, Fkbp5, Nfkbib, Sra1, Vcam1, Ccnh, Sele, Rac1, Stat3, Cebpb, Bcl2l1, Rras2, Il1rn, Cdkn1a, Fkbp4, Nr3c2

Fig. 5.

Impact of 24 h LPS challenge on cardiac transcription of the TLR (upper panel) and interferon signalling paths (lower panel) in wild-type mice (n = 6–8/group). Induced transcripts highlighted in red and repressed in green. Shaded transcripts are altered by LPS by less than the threshold value

Unsurprisingly, many highly responsive transcripts were involved in inflammation (Figs. 3 and 4, Table 5): within the most induced are interferon-related genes (Ifit1, Ifit2, Ifit3, Igtp1, Igtp2, Igtp3, Iigp1, Iigp2, Ifi44 and Irf7) and inflammatory/immune modulators (Lcn2, Saa3, Socs3, S100a8, S100a9, Mpa2l, Cxcl1, Cxcl9, Cxcl10, IL6, Ptx3, Serpina3n, Csf3 and Mt2). Several are potentially injurious to the heart: the most highly induced transcript encodes lipocalin-2, which regulates inflammation and matrix degradation, is implicated in heart failure [58] and promotes cardiac apoptosis [59]; CXCL1 is a potent neutrophil chemoattractant; CXCL9 stimulates cytokine production and T-cell proliferation/recruitment; CXCL10 mediates CXCR3⁺ cell migration and augments inflammation. Conversely, some transcripts encode anti-inflammatory and potentially protective molecules: SERPINA3N (α1-antichymotrypsin) inhibits proteases involved in inflammation; the pentraxin PTX3 is expressed in heart with inflammation and limits cell death; SOCS3 is a negative feedback regulator of IL-6 signalling, implicated in sex-dependent cardiac stress-resistance; metallothionein-2, induced by STAT3-related signalling, mediates cardioprotection and can limit dysfunction in sepsis.

Cardio-depressant molecular profile

Major pathways critical to contractile function were substantially impacted, identifying a ‘cardio-depressed’ molecular profile in hearts of endotoxemic mice (Figs. S18–S21). β-Adrenergic signalling was broadly suppressed (Fig. S18), including reduced transcripts for β₁-adrenergic receptor, G protein, adenylate cyclase, PKA and related signalling elements (Ppp1r14c, Gng11, Prkar2b, Pde7a, Ppp1r3c, Ppp1r14a, Pkia and Adcy7), together with induction of Pde4b (AMP-dependent phosphodiesterase). The PKA pathway itself was substantially suppressed (Fig. S19), including reductions in PKA RIα (Prkar1a), PKA RIIα (Prkar2a), PKA RIIβ (Prkar2b), PKAα (Prkaca) and PKA-Cβ (Prkacb), while PKA RIβ (Prkar1b) was modestly induced (+1.5). Transcripts for G_αs and G_αq also declined.

Cellular Ca²⁺ signalling paths were repressed (Fig. S20), with reductions in key elements including: Camk1d, Ryr3, Casq1, Mef2c, Casq2, Calm1, Hdac9, Myh7b, Tpm2, Myh11, Rcan1, Myl7, Atp2b2, Prkar2b, Tpm3 and Asph. Mitochondrial dysfunction (Fig. S21) is also evidenced by repression of complex I/NADH dehydrogenase components (including Ndufv2 and 3; Ndufs4, 5, 6, 7 and 8; Ndufa3, 4, 5, 6 and 8; Ndufab1, Ndufaf1, Ndufb2, 3, 4, 7, 9, 10 and 11), together with Complex II components (including Sdhc, Sdhd, Uqcrb, Uqcrc1 and Uqcrfs1). Uncoupling proteins Ucp2 and Ucp3 were also induced, while Ucp1 was repressed. Transcript for the major activator of mitochondrial biogenesis (Ppargc1a) was repressed.

Adenosine-related transcripts

There were limited impacts on the adenosinergic system itself, with two- to threefold upregulation of adenosine deaminase, 1.5-fold repression of adenosine kinase, 1.7-fold induction of S-adenosylhomocysteine hydrolase and twofold induction of the ecto-nucleotidase CD39. These changes may modify patterns of cellular adenosine generation vs. uptake and metabolism, potentially altering receptor activation in endotoxemic tissue. A small 1.3-fold rise in Adora2b expression was also detected.

Impact of A_2AR KO on transcriptomic responses to endotoxemia

Interestingly, A_2AR activity does not broadly suppress the effects of endotoxemia on myocardial gene expression, with 90 % of transcriptomic responses unaltered by receptor KO. For example, Fig. 3 presents response profiles for the 25 most induced or repressed transcripts in WT hearts, with most shown to be insensitive to A_2AR KO. Deletion selectively enhanced induction of Lcn2, Igtp, Cxcl5, S100a8, Iigp2, Cxcl2 and Iigp1 and repression of C1qtnf9, Colec11 and Inmt, while reducing induction of Ifit3 and repression of Adipoq, Gpr22, and Scube2, Ifit3 (Fig. 3). These effects support A_2AR modulation of inflammatory and interferon-related signalling responses. Nonetheless, the pattern of LPS-dependent cytokine/chemokine change was largely insensitive to A_2AR KO, with specific enhancement of Cxcl5, Cxcl2, Il6 and Csf3 induction (Fig. 4). Figure 6 summarizes the select effects of A_2AR activity (revealed via KO) on TLR- and interferon-triggered NFκB and JAK-STAT signalling responses to LPS (generally repressing these pathways).

Fig. 6.

Schematic of TLR, IL-1, IL-6 and interferon receptor activation of NFκB and JAK-STAT signalling and transcriptional control. The effects of A_2AR KO- on LPS-dependent gene changes are highlighted. These pathways are critical to cellular responses to LPS and orchestration of inflammation. Specific effects of A_2AR activity (based on effects of receptor KO) on transcriptional responses to LPS are highlighted (red—increased expression; blue—reduced expression)

To gain further insight into these specific effects of A_2AR KO, we identified those LPS-responsive transcripts whose expression changes were increased or reduced ≥1.5-fold by A_2AR KO (Table S9). Effects of LPS on 282 genes were augmented ≥1.5-fold following A_2AR KO, with a further 9 responsive to LPS specifically in KO and not WT hearts (Table S9). The most highly augmented included 25 transcripts increased ≥twofold by KO. Many A_2AR-sensitive transcripts are associated with pro-inflammatory signalling (e.g. Igtp, Lcn2, Cxcl5, S100a8, Iigp2, Cxcl2, Il6, Ifi202b, Hp and Cxcl9), with data supporting inhibitory effects of the A_2AR on the responsiveness of canonical pathways that include the acute phase response, glucocorticoid receptor, Erk/MAPK, HIF1α and JAK-STAT signalling (Table 6).

Table 6.

Top canonical responses to LPS modified by A_2AAR KO (the 15 most promoted or inhibited by A_2AAR KO are shown)

Canonical Pathways	P value	Ratio	Genes
LPS responses enhanced by A2AR KO (countered by A2AR activity)
Acute phase response signalling	7.41E-04	5.06E-02	Hpx, Hp, Rras2, Pik3r1, Cp, Il6, Serpine1, Nr3c1, Orm1
Glucocorticoid receptor signalling	9.33E-04	3.90E-02	Hspa4, Cxcl3, Rras2, Pik3r1, Cdkn1a, Tgfb2, Il6, Stat1, Serpine1, Hspa2, Nr3c1
Glioma invasiveness signalling	1.29E-03	8.47E-02	Timp4, Rras2, Pik3r1, Rhoj, Itgb3
Germ cell-sertoli cell junction signalling	1.45E-03	5.00E-02	Rras2, Tuba8, Pak6, Map3k6, Pak3, Pik3r1, Tgfb2, Rhoj
Angiopoietin signalling	3.16E-03	6.58E-02	Grb14, Rras2, Pak6, Pak3, Pik3r1
ILK signalling	3.55E-03	4.26E-02	Ppp2r3a, Pik3r1, Vegfc, Atf4, Rhoj, Itgb6, Pgf, Itgb3
Ephrin receptor signalling	3.98E-03	4.04E-02	Rras2, Pak6, Pak3, Vegfc, Atf4, Epha4, Efnb3, Pgf
ERK/MAPK signalling	4.37E-03	4.10E-02	Rras2, Pak6, Pak3, Ppp2r3a, Ppp1R3c, Pik3r1, Atf4, Stat1
Pancreatic adenocarcinoma signalling	4.47E-03	5.08E-02	Pik3r1, Cdkn1a, Tgfb2, Vegfc, Stat1, Pgf
HER-2 signalling in breast cancer	5.13E-03	6.17E-02	Rras2, Pik3r1, Cdkn1a, Itgb6, Itgb3
Macrophage NO & ROS production	7.08E-03	3.74E-02	Map3k6, Ppp2r3a, Ppp1r3c, Pik3r1, Rhoj, Irf8, Stat1
Hepatic fibrosis/stellate cell activation	1.05E-02	4.48E-02	Cxcl3, Tgfb2, Vegfc, Il6, Stat1, Pgf
Circadian rhythm signalling	1.12E-02	8.57E-02	Per3, Arntl, Atf4
HIF1α signalling	1.38E-02	4.55E-02	Rras2, Pik3r1, Vegfc, Slc2a4, Pgf
JAK/Stat signalling	1.41E-02	6.06E-02	Rras2, Pik3r1, Cdkn1a, Stat1
LPS responses inhibited by A2AR KO (promoted by A2AR activity)
PXR/RXR activation	6.46E-04	4.4E-02	Rac2, Prkar2b, Cyp2b6
Nicotinate and nicotinamide metabolism	3.98E-03	2.94E-02	Cilp, Art5, Eif2ak2, Bst1
Amyloid processing	4.57E-03	5.08E-02	Rac2, Prkar2b, Capn10
Glutamate receptor signalling	5.89E-03	4.29E-02	Glul, Slc38a1, Homer1
AMPK signalling	9.55E-03	2.40E-02	Rac2, Prkar2b, Adipoq, Eif4ebp1
PRRs in recognition of bacteria & viruses	9.77E-03	3.66E-02	C3, Ddx58, Eif2ak2
NF-κB signalling	1.15E-02	2.58E-02	Rac2, Nfkbie, Btrc, Eif2ak2
NF-κB activation by viruses	1.23E-02	3.61E-02	Rac2, Nfkbie, Eif2ak2
Inhibition of angiogenesis by TSP1	1.55E-02	5.56E-02	Rac2, Sdc1
Role of RIG1-like receptors in antiviral innate immunity	1.66E-02	3.92E-02	Nfkbie, Ddx58
FXR/RXR activation	1.78E-02	2.91E-02	Rac2, Sdc1
TR/RXR activation	1.78E-02	3.03E-02	Rac2, Ucp1
PPARα/RXRα activation	1.86E-02	2.22E-02	Prkar2b, Nfkbie, Adipoq
RANK signalling in osteoclasts	1.95E-02	3.06E-02	Rac2, Nfkbie, Map3k2
Fcγ receptor-mediated phagocytosis in macrophages and monocytes	2.04E-02	2.97E-02	Hmox1, Rac2, Hck

Canonical pathways modified by LPS, ranked according to P-values determined by Fisher’s Exact Test. Also shown is the ratio reflecting the number of molecules in a given path that meet cut-off criteria for differential expression, divided by the total number of molecules in the path

Deletion of the A_2AR reduced or entirely eliminated 134 gene responses to LPS (Table S9). Responses entirely A_2AR-dependent included repression of Sacs, Cidec, Gnb1l, Mtap1b, Msi2, Cdh2, Lpgat1, Tbx3, Slc38a1, Sdc1, Reln, Ext1 and Pvrl3, and induction of Rit1, Ezh1, Eif4ebp1 and Abhd4 (Table S9). The transcripts most sensitive to A_2AR KO included Dnmt3a, Qk, Sema5a, Srpk2, Car3, Ucp1, Rsad2 and Dnajb14. Highly LPS-responsive changes counteracted by A_2AR KO included: Ifit3, Rsad2, Cxcl13, Ms4a6d, Oasl1, Ms4a4c, Sema5a, Tyki and Hmox1. Intrinsic A_2AR activity thus also promotes LPS-dependent shifts in select genes associated with immune/inflammatory processes, including orphan nuclear receptor and PPARα activation, PRR responses to infection, AMPK signalling and NFκB signalling (Table 6).

In terms of biological functions, A_2AR activity reduced LPS responsiveness of paths related to cellular movement, growth, signalling and death, immune cell trafficking and haematological and cardiovascular development (Tables 7 and S10). Conversely, A_2AR activity appears to augment responses in pathways related to metabolism and transport, together with organ, haematological, cardiovascular and lymphoid development (Table 7), with complete details of pathway responses modified by A_2AR KO included in Table S10. Deletion of the A_2AR also influenced multiple toxicological functions; of 35 responses countered by A_2AR KO, 12 were cardiac-specific categories (Table S11), with reduced Adipoq and Hmox1 responses involved in ~half. Of 46 toxicological function responses enhanced by A_2AR KO, a third was cardiac categories. Enhanced responses for Serpine1, Kckn3 and Ppargc1a are involved in a majority of these and are also implicated in cardiac dysfunction.

Table 7.

Functional groupings of genes for which LPS responses were modified by ≥1.5-fold (induction or repression) by A_2AR KO

Functional grouping	P value	Number of genes
LPS responses enhanced by A2AR KO (countered by A2AR activity)
Molecular and cellular functions
Cellular Movement	1.10E-08–5.10E-03	58
Cell-To-Cell Signalling and Interaction	1.78E-06–5.40E-03	46
Cell Death	1.13E-05–4.87E-03	74
Cellular Growth and Proliferation	1.30E-05–5.40E-03	58
Cell Cycle	2.22E-05–4.86E-03	30
Physiological system development and function
Haematological System Development and Function	3.17E-07–5.40E-03	53
Haematopoiesis	3.17E-07–4.79E-03	36
Tissue Morphology	3.17E-07–4.79E-03	38
Immune Cell Trafficking	3.90E-07–5.10E-03	37
Cardiovascular System Development and Function	1.54E-06–4.25E-03	24
Disease and disorders
Cancer	3.71E-08–5.03E-03	82
Immunological Disease	9.17E-08–3.81E-03	72
Skeletal and Muscular Disorders	7.90E-07–3.81E-03	77
Inflammatory Response	1.78E-06–5.05E-03	46
Haematological Disease	2.44E-06–3.68E-03	37
LPS responses inhibited by A2AR KO (promoted by A2AR activity)
Molecular and cellular functions
Carbohydrate Metabolism	2.24E-05–2.33E-02	6
Molecular Transport	2.38E-05–2.61E-02	24
Small Molecule Biochemistry	2.38E-05–2.87E-02	34
Lipid Metabolism	4.28E-05–2.87E-02	14
Cellular Compromise	6.16E-05–2.61E-02	11
Physiological system development and function
Cardiovascular System Development and Function	4.28E-05–2.97E-02	5
Organ Development	4.28E-05–2.33E-02	7
Organismal Functions	9.49E-05–2.61E-02	4
Haematological System Development and Function	2.54E-04–3.11E-02	13
Lymphoid Tissue Structure and Development	2.54E-04–2.61E-02	6
Disease and disorders
Inflammatory Response	6.16E-05–3.11E-02	15
Nutritional Disease	8.22E-05–6.58E-03	10
Genetic Disorder	1.34E-04–3.00E-02	30
Developmental Disorder	2.54E-04–2.61E-02	14
Neurological Disease	2.54E-04–2.61E-02	30

Functional groupings of LPS-responsive cardiac transcripts modified by A_2AR KO (enhanced or repressed) by a factor of ≥1.5-fold. Functional groups derived from IPA analysis are categorized into molecular and cellular functions, physiological system development and function, and disease and disorders, and ranked according to P value ranges determined by a Fisher’s Exact Test. Total numbers of involved genes are also shown

Importantly, a relatively small set of A_2AR responsive genes are implicated in a majority of these A_2AR sensitive biological pathways and processes and can be considered A_2AR-dependent ‘nodes’ or points of regulatory convergence. Of the top 50 pathway responses augmented by A_2AR KO, Pi3kr1 is implicated in 42; Rras2 in 40; Stat1, Vegfc, Pgf and Pak6 each in 12; Atf4 in 11; Cdkn1a in 9 and Rhoj and IL6 each in 8 (Tables 6 and S10). Of the leading 50 canonical responses inhibited by A_2AR KO, Rac2 was implicated in 34, Nfkbie in 21, Prkar2b in 10, Hmox1 and Eif2ak2 each in 6 and Eif4ebp1 and Cyp2b6 each in 5 (Tables 6 and S10). These data point to an influence of intrinsic A_2AR activity on key signalling responses, including G protein, PKA, STAT1 and NFκB-dependent processes (see Supplementary material for additional discussion). While the absence of A_2ARs impacted inflammatory and underlying signalling changes in endotoxemia, paths implicated in endotoxemic cardio-depression (ß-adrenergic and PKA signalling, Ca²⁺ handling, excitation-contraction coupling and mitochondrial function; Figs. S18–S21) were not among those sensitive to A_2AR KO (Table 6), consistent with a lack of effect of A_2AR KO on contractile dysfunction itself (Table 1).

PCR analysis of select transcripts

Quantitative RT-PCR analysis supports microarray-determined changes in transcripts selected for differential responsiveness to LPS and A_2AR KO (Fig. 7). While expression ratios vary slightly between the two methods, a significant linear relationship was apparent between both measures (with a slope > 1 suggesting greater dynamic range for RT-qPCR measurement).

Fig. 7.

Comparison of expression values for select transcripts assessed via array analysis and quantitative real-time PCR. Expression ratios are relative to values in wild-type (WT) hearts treated with normal saline (NS) and are thus shown for WTs treated with LPS for 24 h (WT LPS) and A_2AR KO hearts untreated (KO NS) or treated with LPS (KO LPS). Data are means ± S.E.M, n = 6–8/group

Discussion

The present study characterizes impacts of A_2AR deletion on the myocardial transcriptome, markers of inflammation and cardiac function and injury in healthy and endotoxemic mice. Data indicate A_2AR activity exerts limited effects in un-stressed myocardium, with transcriptomic changes limited to G protein, cAMP/PKA and cGMP/NO signalling downstream of this and other GPCRs (Tables 2 and 3). However, during endotoxemia, absence of A_2ARs exaggerated myocardial injury (and age- and sex-dependent mortality), without substantially modifying patterns of cytokine release, myocardial cytokine/chemokine transcription or contractile depression. The latter is consistent with insensitivity of the ‘cardio-depressant’ profile in endotoxemic hearts to A_2AR KO. Rather, data reveal A_2AR activity selectively influences transcription of regulators of NFκB and JAK-STAT signalling during endotoxemia, which may limit myocardial inflammation and injury. Additional changes with A_2AR KO suggest potential influences on insulin-resistance, hypertrophy/remodelling and vascular control/angiogenesis in endotoxemia.

A_2AR activity and the transcriptome in un-stressed myocardium

Modest impacts of A_2AR KO in un-stressed hearts (Table 2) are consistent with a largely retaliatory or stress-responsive role for myocardial A_2ARs. Indeed, deletion failed to modify cardiac or vascular function, and circulating CRP, haptoglobin and cytokines in healthy animals. Functional annotation of transcripts supports A_2AR-dependent shifts in relaxin, adrenergic, Ca²⁺, PKA, SAPK/JNK and hypertrophic pathways (Tables 3 and S2), involved in cellular growth/movement/death, immune and cell-to-cell signalling, and toxicological processes of fibrosis, cell damage and inflammation. This profile stems from a handful of changes spanning pathways (i.e. Gnb1, Nfat2c, Acta1, Prkar2b, Map3k2 and Pde3b), supporting effects of A_2AR activity on G protein and cAMP/PKA signalling downstream of the receptor [5, 8, 60]. Deletion of the A_2AR has been shown to reduce cAMP and PKA activation in other cell types [61], consistent with impacts of KO here (Table 3). The altered MEKK2 path is also linked to G protein/Rac-dependent signalling distal to this and other GPCRs. In terms of vasoregulatory functions of the A_2AR, shifts in inter-related pathways involved in relaxin signalling, cellular effects of sildenafil and NO signalling (Table 3) support modulation of cGMP/NOS dependent control, while cardiac arteriopathy was identified as a pathologic process sensitive to A_2AR KO (Table 4). These rather limited transcriptomic changes in healthy myocardium are consistent with observations in other tissues. For example, Yu et al. [62] found A_2AR KO alters a very small sub-set of transcripts in healthy striatum (implicating A_2AR sensitive EGR-2 control), with expression changes also modest (a majority ≤twofold). Others report no impact of A_2AR KO on myocardial expression of RAC1, ERK1/2, p38-MAPK or JNK [14], though phospho-activation of the latter kinases was impaired, potentially reflecting shifts in cAMP/PKA and MEKK2 signalling.

Transcriptomic profile of endotoxemic myocardium

Myocardial injury and dysfunction are critical determinants of circulatory changes and mortality with uncontrolled inflammation; however, their mechanistic basis is poorly defined. Transcriptomic interrogation can reveal elements of these complex responses, though there are few analyses of myocardial [41, 42, 49] or cardiomyocyte [43, 49] responses to endotoxin/sepsis. Approximately 15 % of the 25,646 transcripts expressed in murine hearts were modified in endotoxemia (Table S4), encompassing a multiplicity of canonical paths and functions (Tables 5, S5–S7). Many are consistent with those highlighted by Wong et al. in more limited analysis of endotoxemic rats [41] and Rudiger et al. in a rat faecal peritonitis model [49]. The myocardial response involves profound upregulation of immune/inflammatory paths (Figs. 3–5 and S4–S7), the most highly modified including acute-phase response, PRR/TLR and interferon/IRF signalling (Table 5). Underlying NFκB, JAK-STAT and MAPK/PI3K paths are up-regulated (Tables 5, S5 and S7; Figs. S8–S12), with NFκB/JAK-STAT mechanistically linking the top five canonical pathway responses. Integrated signalling via NFκB and JAK-STAT paths thus appears central to myocardial endotoxemia, as in other tissues. In other tissues, these paths are also targeted by A_2ARs to suppress inflammatory/immune responses [44, 45, 58], with KO augmenting NFκB activation in macrophages, for example [6].

Amplified cardiac TLR and interferon signalling

Since uncontrolled inflammation induces cellular injury/death, pro-inflammatory TLR/CD14 signalling is the subject to negative control. However, this path was transcriptionally amplified in endotoxemic myocardium (Fig. 5), including receptor molecules (Cd14, Tlr1, Tlr2, Tlr3 and Tlr4) and LPS-binding protein (Lbp), transduction molecules (Cr3/Mac1 and Cr4), MyD88, TIRAP and MyD88 targets (Il6 and Il1b), MyD88-independent signal components (Tbk1, Cxcl10, Ccl2 and Ccl5) and downstream JAK-STAT signalling (Fig. S9). Upregulated TLR and MyD88-dependent and independent signalling are consistent with changes in rat sepsis [49], though Tlr4, Cd14 and Tirap induction here was not apparent in the rat model. Sweeney et al. [63] recently reported a novel MyD88-independent path linking TLR2/TLR4 signalling to Ppargc1a, encoding the mitochondrial biogenesis co-regulator PGC-1α. However, despite induction of elements of this path here (including Tlr2, Tlr3, Tlr4 and Irf7), cardiac Ppargc1a was repressed by LPS, a response potentially exaggerating mitochondrial dysfunction and countered by A_2AR activity.

Interferon signalling transducing inflammatory/TLR responses was also upregulated (Fig. 5), including a majority of gene targets and the path of IRF activation by PRRs (Figs. S5–S7). This entailed induction of membrane (Tlr2, Tlr3 and Tlr4), cytosolic (Ddx58, Ifih1, Eif2ak2 and Oas1) and extracellular (C1q, C3, C3a and Ptx3) receptors, and downstream mediators (Il6, Irf7 and Rantes). These shifts in TLR/CD14, MyD88-dependent and -independent and interferon/IRF signalling are relevant to temporal expansion of molecular changes [41, 42] and injury progression in endotoxemia: CD14 [64] and TLR4 [65, 66] both mediate cardiac dysfunction and injury and MyD88 signalling promotes cardiac hypertrophy [67], inflammation and injury [68, 69]. These profound responses diverge from in vitro data suggesting dampened/transient impacts of LPS on isolated myocyte NFκB and IκB kinase [43, 63].

Endotoxemic cardio-depression

Cardiomyocyte and myocardial function is LPS-sensitive and depressed in endotoxemia [21, 23, 70, 71] (Table 1). This has been linked to abnormalities in myofibrillar Ca²⁺ sensitivity [70, 71], adrenergic control [71–74] and mitochondrial function [75], together with cell death [23, 76, 77]. Transient changes in preload may also mediate early reversible depression in vivo [78]. Transcriptomic data reveal a cardio-depressant profile entailing suppression of key determinants of contraction, including Ca²⁺, β-adrenergic and PKA signalling, mitochondrial function and electromechanical coupling (Figs. S18–S21). Importantly, and despite other impacts, A_2AR expression did not influence this cardio-depressant profile nor modify contractile depression (Table 1) [23].

Suppression of β-adrenergic and Ca²⁺ signalling is consistent with desensitization in hearts and myocytes [71–73], and transcriptional changes in a rat model of faecal peritonitis [49]. Despite overlap with the latter response, the β₁- rather than β₂-adrenoceptor is depressed in endotoxemic mouse heart (Fig. S18), while reductions in AKAP, PP1, PP2A, NCX and L-type Ca²⁺ channel components observed here were not evident in the peritonitis model. Nonetheless, data collectively implicate β-adrenergic dysfunction as a common component of cardio-depression, consistent with reductions observed in β-adrenoceptor expression [73], tissue noradrenaline and adrenaline [73] and adrenoceptor stimulation of cAMP and Ca²⁺ fluxes [73]. In terms of approaches to inotropic support, coincident depression of adrenoceptor, PKA and Ca²⁺ signalling may limit the value of interventions targeting these effectors. Abnormalities within the contractile apparatus itself (repressed α-tropomyosin, troponin-T, α-actin and titin transcription) may also be relevant. Targeting mitochondrial dysfunction may more broadly improve cardiac outcomes: repression of Complex I components (Fig. S21) is consistent with Complex I specific dysfunction and ROS generation in mitochondria from endotoxemic hearts [75, 79].

Additional cardio-depressant changes include altered TLR4 and fibroblast factor signalling, suppression of substrate metabolism and IGF-1 signalling (Fig. S22) and induction of inhibitory S100a8/S100a9, Icam1, Vcam1, Cybb (NOX2), Ptgs2 (COX2) and the TNF-α receptors Tnfr1 and Fas. Marked induction of S100 A8 and S100 A9 (TLR4 activators promoting endotoxemic injury) has been observed in LPS-treated myocytes, involving MyD88 and NFκB signalling [80]. Intriguingly, two adipokines with opposing actions, relevant to cardiac dysfunction, were among the most responsive to LPS. Pro-inflammatory and injurious lipocalin-2 (Lcn2) was the most induced (~600-fold), consistent with changes in rodent and human myocarditis [59], while anti-inflammatory and cardioprotective adiponectin (Adipoq) was the second most repressed. Lipocalin-2 is induced via IκBζ (+13 with LPS) and with heart failure, ischemia and inflammation [81, 82]. Profound induction may promote dysfunction given its inflammatory [83], pro-death [82, 84] and mitochondrial actions [84]. Current data suggest the A_2AR may beneficially limit LPS-dependent IκBζ induction to suppress injurious lipocalin-2. Highly repressed adiponectin exerts anti-inflammatory, anti-oxidant and cardioprotective effects [85, 86], thus downregulation is also likely to promote inflammation and sensitize myocardium to oxidative-stress and cell death. Curiously, Adipoq repression was reduced with A_2AR KO, suggesting a positive influence of A_2AR activity on this response. These and other changes relevant to pathogenesis of cardiac depression are discussed further in the online Supplementary material.

A_2AR modulation of the endotoxemic transcriptome

Despite well-established anti-inflammatory effects of acute A_2AR agonism, the myocardial transcriptomic response to endotoxemia was largely insensitive to A_2AR KO (Figs. 3 and 4; Tables 7 and S9). Rather than a broadly suppressive impact of A_2AR activity, only 10 % of the transcriptomic response was modified by KO. This selective outcome is consistent with data for cytokine/chemokine transcription and release—the majority of these responses were also unaltered by A_2AR deletion, which specifically modified Il6, Cxcl2, Cxcl5 and Csf3 induction (Fig. 4) and circulating IL-5, haptoglobin and CRP levels (Figs. 1 and 2). These responses are nonetheless relevant to myocardial outcome: IL-6 initiates and expands inflammatory signalling, and CXCL2 and CXCL5 both participate in cardiac inflammation and remodelling. Important IL-6 target genes were highly induced with LPS, including Bcl2l1, Cebpb, Irf1, JunB, Lbp, Socs3 and Timp1. By suppressing IL-6 transcription, potentially through IκBζ induction and STAT1 repression, A_2AR activity may limit cardiac IL-6 signalling. Functional annotation of A_2AR sensitive transcripts does support modulation of acute phase response, JAK-STAT, MAPK, PRR and NFκB pathways (Tables 7, S6 and S10). Figure 6 summarizes these key changes, highlighting impacts of A_2AR KO. Through modifying a small number of key transcript responses (Nfkbie, Nfkbiz, Il6, Lcn2, Stat1, Cdkn1a and Rras2), A_2AR activity may limit expansion of injurious inflammation in endotoxemic myocardium. In contrast, the cardio-depressant molecular profile appears insensitive to A_2AR KO.

NFκB signalling

The A_2AR represses NFκB signalling via multiple mechanisms in non-cardiac cells, including phosphorylation-/SUMOylation-dependent IκB degradation and modulation of the SCF-E3 ubiquitin ligase complex [58]. The absence of A_2ARs did modify the NFκB path in endotoxemic myocardium (Fig. 6), amplifying pro-inflammatory Nfkbiz (IκBζ) induction while countering inhibitory Nfkbie (IκBε) induction. Enhanced transcription of IκBζ and its targets Lcn2 and Il6 with A_2AR KO suggests the receptor may suppress inflammation by inhibiting IκBζ induction and its transcriptional actions, while promoting IκBε induction to limit nuclear translocation of NFκB (Fig. 6).

In contrast, A_2AR KO also reduced induction of molecules promoting NFκB signalling (Fig. 6): Eif2ak2/Pkr inhibits IκBα expression and enhances NFκB signaling and IFN-β expression; Btrc promotes degradation of IκBα and Rac2 promotes cytokine-triggered NFκB signalling and IFN-γ expression. It is unclear what the balance of these changes might be, though repression of the distal transcriptional effector IκBζ is predicted to limit effects of up-stream changes. Failure of A_2AR KO to modify changes in genes recently implicated in cardioprotective effects of NFκB signalling [47] (including induction of Ptx3, Plscr1, Sfi1 and Igfbp3 and repression of Car3, Dkk3, ai605517 and Grhl2) suggests receptor activity might selectively modify injurious rather than protective aspects of NFκB signalling.

JAK-STAT signalling

In non-cardiac cells, A_2AR agonism also inhibits JAK-STAT signalling, via control of SOCS transcription [58] and ubiquitination/degradation of JAK-phosphorylated STATs [87]. Despite no evidence for A_2AR modulation of Socs3 (induced with LPS unaltered by KO), A_2AR deletion did modify the JAK-STAT response, exaggerating induction of both Stat1 and the key activator Il6. Since STAT1 is crucial to LPS-induced apoptosis in non-cardiac cells [88], and mediates injury with ischemic insult [39], A_2AR-dependent suppression is predicted to be protective. Deletion of A_2ARs also enhanced endotoxemic induction of Cdkn1a/p21Cip1/Waf1 (modulator of STAT1-dependent apoptosis and IFN-γ/STAT signalling, linked to poor sepsis outcomes [49]) and the signal transducer Rras2. These data collectively support beneficial A_2AR modulation of JAK-STAT activation in endotoxemic myocardium (Fig. 6).

Select impacts on acute phase response vs. TLR and interferon signalling

The acute phase response is triggered by IL-1, IL-6 and TNF-α and transduced via NFκΒ and JAK-STAT signals. Additional to effects of KO on Il6 and JAK-STAT and NFκB paths, A_2AR activity appears to counter induction of key gene targets (Serpine1, Il6, Cp, Hpx, Hp and Orm1). Conversely, A_2AR activity was also associated with greater induction of target genes C3 and Hmox and reduced induction of the glucocorticoid receptor inhibiting this inflammatory response. While mixed, collective shifts in JAK-STAT/NFκB paths support transcriptional suppression of the acute phase response via A_2AR activity. However, while TLR/interferon paths were among the most highly responsive to LPS, A_2AR KO did not substantially modify these responses (augmenting induction of MyD88-responsive Irf8 and altering downstream NFκB signalling). Major changes in interferon signalling were also largely un-modified by A_2AR KO (Fig. 6), suggesting select impacts of A_2AR activity on elements of the acute phase response yet not associated TLR and interferon signalling.

Novel effects of A_2AR KO

The impact of A_2AR activity is limited primarily to canonical elements of endotoxemia (Tables 6, S10 and S11); however, several of the more A_2AR-sensitive transcriptional responses to LPS hint at novel effects of A_2AR signalling, including modulation of insulin-sensitivity, hypertrophic growth/remodelling and cardiac rhythmicity, together with influencing angiogenesis and vascular control.

Disruption of insulin-dependent glucose metabolism is an important consequence of endotoxemia, and three of the most A_2AR-sensitive transcripts (Ptprf, Glut4/Slc2a4 and Glut12/Slc2a12) govern insulin-dependent glucose uptake (Table S9). Endotoxemic suppression of Glut4 and the secondary insulin-sensitive transporter Glut12 and the induction of Ptprf (encoding protein tyrosine phosphatase, receptor type F; implicated in insulin-resistance) were exaggerated >twofold with A_2AR KO (Table S9). Endotoxemic suppression of Glut4 and glucose uptake is reported in skeletal and cardiac muscle [89]. Conversely, increased expression of Glut4 improves glucose uptake and limits myocardial dysfunction in endotoxemia [89]. These responses to A_2AR KO suggest regulatory influences of A_2AR activity on glucose handling in endotoxemic tissue.

Other highly A_2AR-sensitive transcriptional responses suggest A_2AR modulation of myocardial remodelling, including shifts in Asb14 and Asb15, Ca3 and Ca4 and Dnmt3a and Srpk2. Endotoxemic repression of transcripts for 2 ankyrin repeat and SOCS box (ASB) proteins, Asb14 and Asb15, was substantially exaggerated with A_2AR KO. The ASB family bind and target proteins for degradation and regulate skeletal muscle development, while roles in heart are unclear. The ASB15 protein enhances skeletal muscle protein synthesis [90] and delays differentiation, potentially via modulating MAPK and PI3K/Akt signalling [91]. This control may be important in adaptive response to muscle load/activity. Carbonic anhydrases are also implicated in myocardial hypertrophy, with endotoxemic Car4 induction (the dominant cardiac isoform) exaggerated and Car3 downregulation was inhibited in A_2AR KO hearts. The myocardial roles of these enzymes are only beginning to be unravelled, though they may promote hypertrophic responses by facilitating Na⁺-H⁺ and Cl-HCO₃ exchanger over-activities, while evidence from other cells suggests CAR3 may modify oxidative stress and apoptosis. Similarly, Srpk2 induction was augmented in the absence of A_2ARs, encoding a serine/arginine (SR) protein kinase (SRPK) that phosphorylates SR domain-containing proteins within interchromatin granule clusters/nuclear speckles to regulate pre-mRNA splicing. The SRPK2 protein also plays an important role in cell proliferation and apoptosis. Additionally, downregulation of the methyltransferase transcript Dnmt3a, governing growth and function of embryonic myocytes [92], appears to be countered by A_2AR activity, which may also limit cardiac fibrosis/remodelling [93]. Collectively, this suite of A_2AR responsive changes may limit myocardial hypertrophy and remodelling responses to inflammatory insult. This is consistent with functional groupings sensitive to A_2AR KO, including determinants of cell cycle, growth, proliferation and death and cardiovascular development (Table 7) and shifts in canonical hypertrophy pathways (Tables S10 and S11).

Curiously, A_2AR activity also limited LPS induction of Hcn1 (Table S9). The HCN proteins mediate the pacemaker (funny) current governing cardiac automaticity/excitability. While HCN4 is the most highly expressed, HCN1 is significantly expressed within the conduction network, contributes to cardiac rhythmicity [94] and is up-regulated in hypertrophy and heart failure. Endotoxemic induction may thus promote arrhythmicity, while A_2AR activity appears to suppress this change.

Finally, A_2AR KO modified a broader range of vascular control and growth pathways in endotoxemic (vs. healthy) hearts. Vascular dysfunction is a critical to organ damage and mortality and may involve NOS overactivity in some vascular beds. Deletion of the A_2AR modified NO signalling together with renin-angiotensin signalling (Table S10), while cardiac arteriopathy was identified as a pathological process sensitive to KO (Table S11). These responses support influences of A_2AR signalling on vascular pathology. We have previously shown endotoxemia impairs coronary hyperaemia, a dysfunction mimicked by KO of (and potentially involving) the A_2AR [23]. Additionally, there is an apparent coronary ‘over-supply’ relative to myocardial demand in endotoxemic hearts (Table 1), owing to 25–30 % lower contractile function without reductions in coronary perfusion. The absence of coronary coupling to ventricular activity, described by us in this and other models [95, 96], suggests additional coronary dysregulation (though this effect is neither replicated nor modified by A_2AR KO). Multiple paths/mediators regulating angiogenesis were also sensitive to A_2AR KO in endotoxemic heart, including shifts in VEGF, HIF-1α, angiopoietin, TGF-β, GM-CSF, PDGF and IGF-1 pathways (Table S10) and key regulatory molecules (including exaggerated induction of Il6, Pgf, Tgfb2, Tgfb2r, Angptl4 and Amotl1; exaggerated suppression of Vegfc and reduced suppression of Qk) (Table S9). While the A_2B receptor is more broadly implicated in control of angiogenesis, these changes suggest A_2AR-dependent processes may influence angiogenesis in the context of uncontrolled inflammation.

RT-qPCR confirmation of microarray-detected responses

Data confirm agreement between transcript expression determined via RT-qPCR and microarray methods (Fig. 7), with PCR further highlighting distinct transcriptional effects of A_2AR KO: in some cases, KO eliminates responses to LPS (Acta1); alters baseline yet not LPS-dependent expression (Amid or Dbp); enhances induction (Txnip) or repression (Cidec) in response to vehicle and LPS or reduces gene expression in the vehicle group while negating further changes with LPS (Eif4ebp2 and Slc38a1). Confirming the microarray approach, some of these responses are also functionally relevant. For example, Txnip encodes a stress-responsive protein inhibiting the anti-oxidant/signalling molecule thioredoxin. Reductions in TXNIP inhibit vascular inflammation and TNF-α signalling [97], TXNIP dysregulation promotes inflammatory disease [98] and elevations in TXNIP facilitate apoptosis [99]. Inhibition of Txnip induction by A_2AR activity may thus enhance protective thioredoxin functionality.

Study limitations

Several study limitations are worth noting. While essential genesis of cardiac injury is studied and understood within the in situ organ, this entails experimental limitations inherent to in vivo studies of organ dysfunction in sepsis/endotoxemia [15, 16, 20, 21, 24, 41, 42, 49]. Organ injury in these settings not only involves intrinsic organ-specific mechanisms but also influenced by extrinsic factors, including shifts in systemic inflammation, haemodynamics and neuroendocrine influences (with relative impacts of these factors difficult to delineate). Although we assess the intrinsic myocardial dysfunction in ex vivo tissue (together with in vivo markers of cardiac damage), we cannot isolate potential influences of A_2AR KO on cardiac loading, neurohumoral factors or indeed systemic inflammation. That said, while A_2AR KO augmented some inflammatory markers, systemic and cardiac cytokine responses were largely insensitive to KO and the myocardial response was very selectively modified, indicating distinct effects of A_2AR activity on cardiac injury processes. We are also unable to detail cell-specific origins of myocardial transcriptional changes. Migrating inflammatory cells could influence the transcriptomic profile for intact myocardium, though, as detailed in the Supplementary material, the expression profile of endotoxemic myocardial tissue is inconsistent with major contamination from such cells. An added limitation relates to the intriguing observation of both age- and sex-dependent mortality effects of LPS and A_2ARs (Fig. S3). This unfortunately precluded any detailed interrogation of these outcomes due to poor survival in older KO mice. Future work might focus specifically on responses to LPS/sepsis in clinically relevant aged cohorts, correlating age-dependent transcriptomic and phenotypic outcomes. Finally, while profound transcriptional changes observed in the current profiling study are predicted to translate to functionally relevant protein changes, this exploratory analysis does not directly confirm altered protein expression.

Conclusions

Deletion of the A_2AR induces modest effects in healthy myocardium, shifting transcription of G protein coupled cAMP/PKA, MEKK2 and cGMP/NO signalling downstream of this and other GPCRs, without impacting cardiac function. However, the receptor may play a retaliatory role in selectively suppressing inflammatory signalling and injury, yet, not contractile depression, in endotoxemic myocardium. Cardiac endotoxemia itself is characterized by profound upregulation of acute-phase response, PRR/TLR and interferon signalling and cell death and remodelling pathways, together with broad suppression of primary determinants of contractility (Ca²⁺, ß-adrenergic and PKA signalling; mitochondrial function; electromechanical coupling) and induction of cardio-depressant genes (Lcn2, S100a8/S100a9, Icam1, Vcam1, Nox2, Cox2, Tnfr1 and Fas). This complex transcriptome is selectively A_2AR sensitive, with effects of KO implicating modulation of key regulatory molecules (Nfkbie, Nfkbiz, Il6, Lcn2, Stat1, Cdkn1a and Rras2) to suppress myocardial JAK-STAT/NFκB and pro-inflammatory IL-6 and TLR signalling, together with influencing determinants of insulin-sensitivity, hypertrophy/remodelling and vascular function/angiogenesis. In contrast, endotoxemic suppression of β-adrenergic, PKA, Ca²⁺ signalling, electromechanical and mitochondrial function pathways appears insensitive to A_2AR KO, as does contractile dysfunction itself.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.